Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
about
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapyDe-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinomaNon-surgical interventions for human papilloma virus-positive local advanced oropharyngeal squamous cell cancerCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewChallenges of Using High-Dose Fractionation Radiotherapy in Combination TherapyMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsHPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment StrategiesMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerAdvanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approachesMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaBiomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerIndividualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresAn overview of the rare parotid gland cancerThe current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neckThe role of microRNA in head and neck cancer: current knowledge and perspectivesThe role of systemic treatment before, during, and after definitive treatmentRadiotherapy and "new" drugs-new side effects?Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approachesNanoparticle-based targeted therapeutics in head-and-neck cancerHuman papillomavirus induced transformation in cervical and head and neck cancersPrimary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancerMonoclonal antibodies for the treatment of cancerWhat is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyAssociation of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or ..Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaToward the use of precision medicine for the treatment of head and neck squamous cell carcinomaMolecular Aspects of Head and Neck Cancer TherapyEpidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinomaCurrent Status and Future Prospects for Esophageal Cancer TreatmentManagement of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?NF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma.p16, Cyclin D1, and HIF-1α Predict Outcomes of Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Definitive Intensity-Modulated Radiation Therapy.Intimal-medial thickness and carotid arteries lumen in irradiated patients for head and neck cancer: preliminary data of an observational study.In vivo optimisation study for multi-baseline MR-based thermometry in the context of hyperthermia using MR-guided high intensity focused ultrasound for head and neck applications.Evidence-based review of treatment options for patients with glottic cancer.Standardized data collection to build prediction models in oncology: a prototype for rectal cancer.Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
P2860
Q24187274-D3C7AD39-8AF3-4B4C-8C7E-B5DE22CFFF09Q24200362-3B0D7CB3-0B49-46DC-A423-3647C7D0A979Q24202687-0C40CF85-72D6-47BA-B605-8E54AB7F737AQ26740067-F8A3ADC6-423C-49EA-927C-61D68C41D81BQ26742107-6ECA111A-66C0-43ED-A394-626BE8055D3BQ26750719-20922527-26FE-42FB-8230-756AA144318EQ26752584-43BF6B8C-CCC2-4F9E-A869-958DFDB4D03BQ26766638-C3D506C8-6A12-4214-AB9F-8148CEC39926Q26767046-E00AB64B-1B2F-4ACC-8D06-A280C6C8D0A6Q26767182-AD676DED-99C4-403D-AFF4-C0E834DE7DCBQ26774605-FABCE38D-11D8-416B-990B-954024194969Q26776198-3A00456E-C8CE-4A60-B9A1-7D4216955640Q26824989-FCC8E854-2BC5-422B-AEC7-B3AE37B448D9Q26830495-AA85F4C8-123F-40C9-8479-18EEBB516F4AQ26851256-4903536C-CFF6-4100-B58D-081E3A38412DQ26859285-5967D3F1-E69E-4B41-B55A-5DA6DFF78BACQ26861498-2FF65135-37B1-48D0-A8C4-F8A2F2397858Q26995360-05DBAF24-771A-44BE-9B7D-F72A7966FA1FQ26999699-A2E3A76B-08F7-4132-904C-220618D62C11Q27003141-9E2D9254-EF57-4642-A345-C68FFB2B90C0Q27009148-C899799C-2EA4-438B-AB71-DFB003A7B19AQ27025966-C3B8C485-23CC-47D6-8888-081DAA87E09EQ27026269-EF0B3E8E-474F-4B38-AF07-43E01C1523A4Q27690634-4FBD93FE-7067-42B2-BEB6-5B6F60617B3EQ27851592-94DC804F-2629-48AC-92AB-0F417CD8FC6CQ27852901-157A3C66-4C7B-4AEC-9056-554D76F8C140Q27853302-DBA933DD-9E9A-44C3-B2AB-5102F33B8E7DQ28071998-ADCCE8F7-1443-477E-A09A-EDDA1D25790FQ28074691-9FBBDF85-416F-408F-8659-0EFA7D98CD86Q28082815-B8E8D006-F0E3-4FE6-9E5A-2CF03FA8CEDAQ28543724-04E96691-351D-4E50-8B4F-7F7E3D6AEBA2Q30240008-83292A0D-42E5-48B9-B2A9-0CC7313DFBCFQ30252081-8D3DDD72-D85E-494D-8577-E1DF0F3DC8D6Q30300214-926C5173-C75F-4B76-8D5B-8A2A78AEC3CFQ30425570-53826E20-C71C-49BA-BDC5-88AC6E50298CQ30596784-88B4755A-3386-41F2-937D-FA53FF60E053Q30872312-842F4B87-5A5F-49C9-A494-4ED0C420D054Q31032091-E6457CA3-8710-4C5A-B94B-71AC6AF3032CQ31032455-6E481ED1-9B30-47F1-99FA-AD65F6371D79Q33162775-AFDD7571-79D7-4C40-803E-4DA940A7E890
P2860
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@ast
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@en
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@nl
type
label
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@ast
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@en
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@nl
prefLabel
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@ast
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@en
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@nl
P2093
P921
P1433
P1476
Radiotherapy plus cetuximab fo ...... mab-induced rash and survival.
@en
P2093
Christopher U Jones
David Raben
Eric K Rowinsky
Hagop Youssoufian
James A Bonner
Jordi Giralt
Junming Zhu
K Kian Ang
Paul M Harari
Ranjan K Sur
P356
10.1016/S1470-2045(09)70311-0
P50
P577
2009-11-10T00:00:00Z